⌕
AMGEN · AMGN · Nasdaq
Tenet 47 · Mixed
Compare
$457.93−0.95%At closeTenet 47 · Mixed
$457.93−4.39 (−0.95%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
$456.90−1.03 (−0.22%)
After hours: Nov 17, 2026, 6:19 PM ET

AMGEN (AMGN) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is AMGN's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● 24/7 Wall StreetNov 17, 2026 · 11:52 ETEARNINGS EXPECTED BY FEB 3
Amgen Has Raised Its 2026 Outlook Twice, and $1,000 From Five Years Ago Is Now Worth More Than $2,500

Prolia and XGEVA are collapsing under biosimilar pressure, yet Amgen keeps lifting its guidance. Which newer drugs are filling the gap, and what could still derail a stock trading near a 52-week high?…

AMGN −0.9% todayRead at source ↗
● Defense WorldNov 14, 2026 · 04:41 ETEARNINGS EXPECTED BY FEB 3
5,000 Amgen Inc. $AMGN Shares Sold by 10Elms LLP

10Elms LLP reduced its position in Amgen Inc. (NASDAQ: AMGN) by 85.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 86…

AMGN −0.9% todayRead at source ↗
● Defense WorldNov 14, 2026 · 03:47 ETEARNINGS EXPECTED BY FEB 3
1,582 Amgen Inc. $AMGN Shares Bought by Allworth Financial LP

Allworth Financial LP raised its stake in shares of Amgen Inc. (NASDAQ: AMGN) by 2.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional inves…

AMGN −0.9% todayRead at source ↗
● The Motley FoolNov 13, 2026 · 17:42 ET
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

Amgen maintains a massive global footprint and a highly diversified portfolio of medicines for serious conditions. Vertex Pharmaceuticals dominates the cystic fibrosis market and is expanding into gene editing and pain m…

AMGN −0.9% todayRead at source ↗
● BenzingaNov 11, 2026 · 10:06 ETEARNINGS EXPECTED BY FEB 3
Amgen Experimental Drug Shows Symptom Reductions in Chronic Autoimmune Disease That Impacts Tears

Amgen Inc. (NASDAQ:AMGN) announced positive Phase 3 results showing dazodalibep significantly reduced systemic disease activity and key symptoms in patients with Sjögren's disease, a chronic autoimmune disease in which t…

AMGN −0.9% todayRead at source ↗
● ReutersNov 11, 2026 · 08:07 ET
Amgen's experimental Sjogren's drug meets late-stage trial goal

Amgen's experimental Sjogren's drug meets late-stage trial goal…

AMGN −0.9% todayRead at source ↗
● PRNewsWireNov 11, 2026 · 08:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 3
AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE

Only Global Phase 3 Trial to Show Clinically Meaningful Improvements in Systemic Disease Activity and Patient-Reported Symptoms of Sjögren's Disease THOUSAND OAKS, Calif., Nov. 11, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMG…

AMGN −0.9% todayRead at source ↗
● 24/7 Wall StreetNov 10, 2026 · 13:17 ET
Amgen vs. Regeneron: Higher Dividends Now or Bigger Growth Later?

One biotech pays retirees a bigger check today, while the other carries no net debt and is growing far faster. We put Amgen and Regeneron side by side on income, valuation, and growth to see which one earns a spot in a r…

AMGN −0.9% todayRead at source ↗
● PRNewsWireNov 9, 2026 · 16:00 ET
NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM

Independent VESALIUS-CV Analysis Finds Repatha Highly Cost-Effective in High-Risk Patients Without a Prior Heart Attack or Stroke Long-Term FOURIER External-Control Analysis Shows Repatha Associated With 29% Lower Risk o…

AMGN −0.9% todayRead at source ↗
● Zacks Investment ResearchNov 9, 2026 · 10:01 ET
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.…

AMGN −0.9% todayRead at source ↗
● 24/7 Wall StreetNov 8, 2026 · 09:09 ET
Amgen's Dividend Has Grown 800% Since 2011. Here's What It Pays Today

Amgen has raised its payout every year since 2011, yet the pace of those raises is cooling just as patent cliffs and drug price controls close in. One number shows whether the next raise, due soon, will hold up.…

AMGN −0.9% todayRead at source ↗
● Defense WorldNov 6, 2026 · 05:19 ETEARNINGS EXPECTED BY FEB 3
1,809 Amgen Inc. $AMGN Shares Acquired by Alta Advisers Ltd

Alta Advisers Ltd lifted its stake in shares of Amgen Inc. (NASDAQ: AMGN) by 85.7% during a recent quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3…

AMGN −0.9% todayRead at source ↗
● Defense WorldNov 6, 2026 · 04:27 ETEARNINGS EXPECTED BY FEB 3
Boston Trust Walden Corp Sells 15,695 Shares of Amgen Inc. $AMGN

Boston Trust Walden Corp trimmed its holdings in Amgen Inc. (NASDAQ: AMGN) by 18.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund …

AMGN −0.9% todayRead at source ↗
● The Motley FoolNov 5, 2026 · 11:05 ET
Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?

Amgen produces strong revenue growth and healthy margins by focusing on complex biological therapies and rare diseases. Pfizer maintains a massive global reach and offers a more conservative balance sheet with a lower va…

AMGN −0.9% todayRead at source ↗
● PRNewsWireNov 5, 2026 · 09:00 ETEARNINGS EXPECTED BY FEB 3
REPATHA® LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDY

Findings Represent Largest and Most Rigorous Head-to-Head Real-World Outcomes Analysis of Repatha and Ezetimibe  Study Examined More Than Half a Million Adults Living with Heart Disease Results Provide Important New Clin…

AMGN −0.9% todayRead at source ↗
● Defense WorldNov 5, 2026 · 06:35 ETEARNINGS EXPECTED BY FEB 3
Amgen Inc. $AMGN Shares Sold by AIA Group Ltd

AIA Group Ltd cut its holdings in Amgen Inc. (NASDAQ: AMGN) by 25.8% in a recent quarter, according to its most recent 13F filing with the SEC. The firm owned 15,607 shares of the medical research company's stock after s…

AMGN −0.9% todayRead at source ↗
● Defense WorldNov 5, 2026 · 04:52 ETEARNINGS EXPECTED BY FEB 3
2,369 Shares of Amgen Inc. $AMGN Bought by First Nebraska Trust Co

First Nebraska Trust Co acquired a new stake in shares of Amgen Inc. (NASDAQ: AMGN) during a recent quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The insti…

AMGN −0.9% todayRead at source ↗
● BenzingaNov 4, 2026 · 12:44 ETEARNINGS EXPECTED BY FEB 3
Amgen Analyst Likes Diversified Business, Remains Patient Until MariTide Obesity Data

Amgen Inc. (NASDAQ:AMGN) shares are trading close to its 52-week high on Wednesday after the company reported better-than-expected third-quarter financial results and raised its fiscal 2026 guidance.…

AMGN −0.9% todayRead at source ↗
● PRNewsWireNov 3, 2026 · 16:01 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 3
AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS

THOUSAND OAKS, Calif., Nov. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the third quarter of 2026.…

AMGN −0.9% todayRead at source ↗
● PRNewsWireOct 28, 2026 · 16:30 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 3
AMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTS

THOUSAND OAKS, Calif., Oct. 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2026 financial results on Tuesday, November 3, 2026, after the close of the U.S. financial ma…

AMGN −0.9% todayRead at source ↗
● PRNewsWireOct 27, 2026 · 16:00 ETCOMPANY'S OWN WORDS
AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026

Phase 3 OASIZ-301 Study of Dazodalibep in Sjögren's Disease Shows Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity and Patient-Reported Dryness New Long-Term UPLIZNA Data in Ig…

AMGN −0.9% todayRead at source ↗
● PRNewsWireOct 26, 2026 · 17:52 ETCOMPANY'S OWN WORDS
AMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS

THOUSAND OAKS, Calif., Oct. 26, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of David W.…

AMGN −0.9% todayRead at source ↗
● PRNewsWireOct 24, 2026 · 10:30 ETEARNINGS EXPECTED BY FEB 3
IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than Tripled Late-Breaking Phase 3 DeLLphi-305 Results  Presented in ESMO Presidential Symposium and Simultan…

AMGN −0.9% todayRead at source ↗
● PRNewsWireOct 20, 2026 · 16:15 ETCOMPANY'S OWN WORDS
AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026

THOUSAND OAKS, Calif., Oct. 20, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society of Medical Oncology Congress (ESMO) 2026 on Saturday…

AMGN −0.9% todayRead at source ↗
● PRNewsWireOct 20, 2026 · 09:00 ET
TEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS

Symptom Improvements Versus Placebo at Week 24 Were Sustained Through Week 52 Statistically Significant Total Endoscopic Remission with No Visible Inflammation or Fibrosis Attained Versus Placebo at Week 52 THOUSAND OAKS…

AMGN −0.9% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 3. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA31−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just AMGN · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.